PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions

Poly(ADP-ribose) polymerase (PARP) inhibitors cause targeted tumour cell death in homologous recombination (HR)-deficient cancers, including BRCA-mutated tumours, by exploiting synthetic lethality. PARP inhibitors are being evaluated in late-stage clinical trials of ovarian cancer (OC). Recently, ol...

Descripción completa

Detalles Bibliográficos
Autores principales: Konecny, G E, Kristeleit, R S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5104889/
https://www.ncbi.nlm.nih.gov/pubmed/27736844
http://dx.doi.org/10.1038/bjc.2016.311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5104889/
https://www.ncbi.nlm.nih.gov/pubmed/27736844
http://dx.doi.org/10.1038/bjc.2016.311

Ejemplares similares